SCHEMBL5058377

SCHEMBL5058377

C=C(O[Si](C)(C)C)c1ccc(N2CCOCC2)cc1O[Si](C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKDC P78527 4/20 0.45
▸ HIF1A Q16665 1/20 0.42
▸ ALDH1A1 P00352 5/20 0.41
▸ KDM4E B2RXH2 4/20 0.41
▸ MAPT P10636 4/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ HTT P42858 2/20 0.41
▸ THRB P10828 2/20 0.41
▸ INSR P06213 1/20 0.41
▸ ALK Q9UM73 1/20 0.41
▸ LRRK2 Q5S007 1/20 0.40
▸ PIK3CD O00329 2/20 0.39
▸ PIK3CA P42336 2/20 0.39
▸ PIK3CB P42338 2/20 0.39
▸ PIK3CG P48736 2/20 0.39
▸ HSD17B10 Q99714 3/20 0.38
▸ HPGD P15428 3/20 0.38
▸ ALOX15 P16050 2/20 0.38
▸ PTK2 Q05397 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10473235 0.75 HIF1A (0.59) PRKDCHIF1AALDH1A1KDM4EMAPT
SCHEMBL10473839 0.69 PRKDC (0.54) PRKDCHIF1AALDH1A1KDM4EMAPT
SCHEMBL4839678 0.68 HIF1A (0.63) PRKDCHIF1AALDH1A1KDM4EMAPT
SCHEMBL10687021 0.68 HIF1A (0.54) PRKDCHIF1AALDH1A1KDM4EMAPT
SCHEMBL4989973 0.67 HIF1A (0.65) PRKDCHIF1AALDH1A1KDM4EMAPT
SCHEMBL12316369 0.67 HIF1A (0.62) PRKDCHIF1AALDH1A1KDM4EMAPT
SCHEMBL30263167 0.67 HIF1A (0.62) PRKDCHIF1AALDH1A1KDM4EMAPT
SCHEMBL4127023 0.67 PRKDC (0.57) PRKDCHIF1AALDH1A1KDM4EMAPT
SCHEMBL19500869 0.67 HIF1A (0.62) HIF1AALDH1A1KDM4EMAPTMEN1
SCHEMBL4291936 0.66 ALDH1A1 (0.60) PRKDCHIF1AALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242115-B2 Inhibit DNA-dependent protein kinase; reduced side effects caused by radiation and chemotherapy drugs LUITPOLD PHARMACEUTICALS, INC. (US) 2012-08-14 — — US disclosed
US-20080090782-A1 Materials and methods to potentiate cancer treatment LUITPOLD PHARMACEUTICALS, INC. (US) 2008-04-17 — — US disclosed
US-7179912-B2 Materials and methods to potentiate cancer treatment ICOS CORPORATION (US) 2007-02-20 — — US disclosed
EP-1351946-A2 MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT ICOS CORPORATION (US) 2003-10-15 — — EP disclosed
US-20020165218-A1 Materials and methods to potentiate cancer treatment LUITPOLD PHARMACEUTICALS, INC. 2002-11-07 — — US disclosed
WO-2002020500-A2 MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT ICOS CORPORATION (US) 2002-03-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090782-A1 Materials and methods to potentiate cancer treatment DCK, CHEK2, CHEK1 PRKDC 17/4885HIF1A 881/4885ALDH1A1 3519/4885
US-20020165218-A1 Materials and methods to potentiate cancer treatment DCK, CHEK2, CHEK1 PRKDC 17/4885HIF1A 881/4885ALDH1A1 3519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback